Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level904 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03528785 | A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer(nITRo) | unknown | Phase 2 | 67 | Centro Ricerche Cliniche di VeronaOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT01676259 | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer(PROTACT) | unknown | Phase 2 | 80 | Silenseed LtdINDUSTRY | 2 |
| Jul 2, 2021 |
| clinicaltrials |
| NCT03451773 | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2021 | clinicaltrials |
| NCT00031694 | Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2021 | clinicaltrials |
| NCT04907864 | Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE)(MIRACLE) | unknown | Phase 2 | 112 | Kil Yeon LeeOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04814485 | Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 25, 2021 | clinicaltrials |
| NCT01459614 | Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer | completed | Phase 2 | 44 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT04083651 | A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Bausch Health Americas, Inc.INDUSTRY | 1 | May 7, 2021 | clinicaltrials |
| NCT02562898 | Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 18 | Margaret TemperoOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT03959150 | Metronomic Chemotherapy With Capecitabine for Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 231 | Ruijin HospitalOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT01077986 | Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 35 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT01210911 | Metformin Combined With Chemotherapy for Pancreatic Cancer(GEM) | completed | Phase 2 | 120 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT02311361 | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2021 | clinicaltrials |
| NCT00521404 | Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer | completed | Phase 2 | 65 | Daiichi SankyoINDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04739046 | An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy | unknown | Phase 2 | 12 | Seoul National University Bundang HospitalOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT02985801 | PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 16 | Massimo Raimondo, M.D.OTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT01206296 | Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | terminated | Phase 2 | 9 | Medstar Health Research InstituteOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT00112658 | Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 / Phase 3 | 342 | UNICANCEROTHER | 1 | Mar 8, 2021 | clinicaltrials |
| NCT00066677 | Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer | terminated | Phase 2 | 32 | Fox Chase Cancer CenterOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT00376948 | Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 1, 2021 | clinicaltrials |
| NCT01838317 | A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas | completed | Phase 2 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 1, 2021 | clinicaltrials |
| NCT03374293 | Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer | unknown | Phase 2 | 21 | Shixiu WuOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT02921737 | TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003) | terminated | Phase 2 | 7 | University of FloridaOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03415802 | Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer | completed | Phase 2 | 32 | Aiping ZhouUNKNOWN | 1 | Feb 1, 2021 | clinicaltrials |
| NCT04723030 | The Transformation of Locally Advanced Pancreatic Cancer. | unknown | Phase 2 | 30 | Peking UniversityOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT03986294 | Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer(NAPAN) | unknown | Phase 2 | 122 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT03585062 | Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer | terminated | Phase 2 | 40 | Zhejiang Provincial People's HospitalOTHER | 1 | Jan 8, 2021 | clinicaltrials |
| NCT00003531 | Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer | terminated | Phase 2 | 15 | Burzynski Research InstituteOTHER | 1 | Jan 7, 2021 | clinicaltrials |
| NCT03989310 | An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03042780 | FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT04183478 | The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 600 | RenJi HospitalOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT01397019 | Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours | completed | Phase 2 | 56 | Per PfeifferOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03180437 | Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 62 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT00026104 | Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer | completed | Phase 2 | 154 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00114179 | Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02459652 | Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer | completed | Phase 2 | 57 | Japan Adjuvant Study Group of Pancreatic CancerOTHER | 1 | Oct 27, 2020 | clinicaltrials |
| NCT03509298 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04581876 | The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer | unknown | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Oct 9, 2020 | clinicaltrials |
| NCT04571489 | A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer | unknown | Phase 2 | 60 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT00493441 | AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer | terminated | Phase 2 | 28 | Vertex Pharmaceuticals IncorporatedINDUSTRY | 1 | Sep 30, 2020 | clinicaltrials |
| NCT02289898 | Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma(YOSEMITE) | completed | Phase 2 | 207 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 6 | Sep 28, 2020 | clinicaltrials |
| NCT00429858 | Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer | terminated | Phase 2 | 21 | Andrew KoOTHER | 1 | Sep 18, 2020 | clinicaltrials |
| NCT03038477 | A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT02717091 | Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer | unknown | Phase 2 | 50 | Nagoya UniversityOTHER | 0 | Sep 10, 2020 | clinicaltrials |
| NCT04520386 | OMT-111 for Terminal Stage Solid Tumors | unknown | Phase 2 | 78 | MetiMedi PharmaceuticalsINDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT00769483 | MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 81 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Aug 2, 2021source: clinicaltrials